These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 22067201

  • 1. The price of tenofovir-emtricitabine undermines the cost-effectiveness and advancement of pre-exposure prophylaxis.
    Keller SB, Smith DM.
    AIDS; 2011 Nov 28; 25(18):2308-10. PubMed ID: 22067201
    [No Abstract] [Full Text] [Related]

  • 2. [Budget impact of a set-dose combination of efavirenz-emtricitabine-tenofovir in the treatment of patients infected with HIV-1].
    Oyagüez I, Casado MA, Cotarelo M, Ramírez-Arellano A, Mallolas J.
    Farm Hosp; 2009 Nov 28; 33(5):247-56. PubMed ID: 19775575
    [Abstract] [Full Text] [Related]

  • 3. Pre-exposure prophylaxis accessibility research and evaluation (PrEPARE Study).
    King HL, Keller SB, Giancola MA, Rodriguez DA, Chau JJ, Young JA, Little SJ, Smith DM.
    AIDS Behav; 2014 Sep 28; 18(9):1722-5. PubMed ID: 25017425
    [Abstract] [Full Text] [Related]

  • 4. Preexposure chemoprophylaxis for HIV prevention.
    Lee DH, Vielemeyer O.
    N Engl J Med; 2011 Apr 07; 364(14):1372-3; author reply 1374-5. PubMed ID: 21470026
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
    Brogan AJ, Talbird SE, Cohen C.
    Value Health; 2011 Apr 07; 14(5):657-64. PubMed ID: 21839403
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
    Sánchez-de la Rosa R, Herrera L, Moreno S.
    Clin Ther; 2008 Feb 07; 30(2):372-81. PubMed ID: 18343275
    [Abstract] [Full Text] [Related]

  • 8. [Pre-exposure prophylaxis for HIV transmission? No, unless].
    Boeke AJ, Heijnen AM.
    Ned Tijdschr Geneeskd; 2013 Feb 07; 157(27):A6359. PubMed ID: 23838404
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice.
    Li J, Dufrene SL, Okulicz JF.
    Ann Pharmacother; 2014 Apr 07; 48(4):507-18. PubMed ID: 24473492
    [Abstract] [Full Text] [Related]

  • 12. Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition.
    de Lastours V, Fonsart J, Burlacu R, Gourmel B, Molina JM.
    Antimicrob Agents Chemother; 2011 Oct 07; 55(10):4905-7. PubMed ID: 21788466
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Preventing HIV in women--still trying to find their VOICE.
    Saag MS.
    N Engl J Med; 2015 Feb 05; 372(6):564-6. PubMed ID: 25651251
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Pre-exposure prophylaxis for the prevention of sexual HIV transmission; new preventative strategy using tenofovir/emtricitabine].
    Boot J, Rump BO, Boucher CA, Op de Coul EL, van Agtmael MA, van de Vijver DA, Burger DM, Fanoy EB.
    Ned Tijdschr Geneeskd; 2013 Feb 05; 157(27):A6063. PubMed ID: 23838402
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.